Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2007

View Archived Issues

Avigen compound inhibits TFPI in hemophilia A plasma, enhancing factor VIII activity

Botulinum toxin type B effective in sialorrhea in amyotrophic lateral sclerosis patients

ADAM inhibitors, a promising approach for HER2+ cancer therapy

Recent Solvay patent reports new antipsychotic agents

Recent Millennium patent reports novel antithrombotic agents

Activity of obatoclax investigated in multiple studies

HIV replication inhibitors prepared and tested at Boehringer Ingelheim

Recent patents impart new agents for the treatment of inflammatory disorders

AMG-479 to be evaluated in phase II study

Connexin 43-expressing stem cell transplants protect against ventricular arrhythmia /News in Context

Nuvelo initiates phase II CARNEROS-1 trial of alfimeprase for acute ischemic stroke

Genentech to initiate phase II clinical testing in 2008 of Hedgehog antagonist drug candidate

Biovitrum completes patient enrollment in phase II clinical trial of BVT-115959

Merck & Co. files IND application with FDA for cancer vaccine targeting telomerase

ReVance Therapeutics and Medicis enter strategic collaboration

Mitsubishi Tanabe Pharma reports positive preclinical data on novel tyrosine kinase inhibitor AV-412

Peplin reports positive results from phase IIa clinical trial of PEP-005 for actinic keratosis

Novo Nordisk reports positive clinical results from one-year monotherapy study of liraglutide

Ceregene reports positive long-term follow-up results from phase I clinical trial of CERE-120

Chroma announces results from phase I study of cancer therapy CHR-2797

Savient reports positive results from GOUT 1 and 2 phase III trials of Puricase

Positive results from phase II clinical trial of R-788 for rheumatoid arthritis

NsGene receives approval to initiate phase Ib clinical study of NsG-0202 for AD

GSK commences subject screening in phase I clinical of Theravance's GSK-1160724

ZymoGenetics and Merck Serono initiate phase II/III clinical trial of atacicept

Japan's NHI drug reimbursement price list includes Chugai's Tarceva

VGX Pharmaceuticals discontinues development of VGX-410C for HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...